CAMBRIDGE, Mass. — Xennex Inc. (Xennex) announced today the release of GeneCards®, Version 3.07, available at www.genecards.org.

The new GeneCards release includes 68,445 Entries, 32,088 of them with symbols approved by the HUGO gene nomenclature committee. It provides several new features, integrated from a variety of sources, including:

Ensembl Pan Taxonomic Compara: Orthologs from non-eukaryotic domains were added in the Orthologs section.

STRING: New Interaction Network Preview image in the Pathways and Interactions section.

MGI: New direct listing for mouse knockouts in the Function section.

GeneALaCart: Various new features including microRNAs and bound targets have been added to the Function section, the Pathways and Interactions section, the Orthologs section, and the Genomic Variants section.

New links to Cell Lines in the Function section, custom synthetic genes, with links to Protein Engineering Gene Synthesis and Variant Synthesis, in the Function, Transcripts, and Genomic Variants sections. New links to Small Molecules in the Drugs and Compounds section, ELISAs and Cell Lines in the Proteins and Function sections, QuantiFast Probe-based Assays in the Transcripts and Expression sections and new Pathways in the Pathways and Interactions section.

In 2010, GeneCards Version 3.0 replaced the previous platform, incorporating significantly upgraded infrastructure, including a comprehensive relational biological database, and a novel, sophisticated and speedier search engine. It includes GeneALaCart, a batch-querying application that allows retrieval of information about multiple genes in a batch query, and an enhanced GeneDecks Version 3, which makes use of the new GeneCards relational database for complex analyses on sets of genes. With GeneCards Version 3.0, Xennex’s customers are able to integrate GeneCards data into their internal systems, and perform comprehensive data mining. These features are also described in Safran et al. GeneCards Version 3: the human gene integrator. Two other recent publications describing GeneCards features include Stelzer et al. In-silico Human Genomics with GeneCards, as well as Harel et al. Omics Data Management and Annotation, Chapter 3. These, and a complete list of 28 GeneCards publications, can be found via http://genecards.org/publications.shtml.

Dr. David Warshawsky, Chairman of Xennex, stated: “We are delighted to see the continued improvement GeneCards features and content utilizing the 3.0. platform. This platform received very positive feedback from existing and new users in academia and industry. Ongoing GeneCards improvement continues to enhance the cutting-edge research in various fields of biology and medicine, and in the discovery and development of diagnostics and therapeutics.”

About GeneCards®

GeneCards® (http://www.genecards.org/) is a searchable, integrated, database of human genes that provides concise genomic, transcriptomic, genetic, proteomic, functional and disease related information on all known and predicted human genes. Information is featured in 20 GeneCards sections and includes orthologies, disease relationships, mutations and SNPs, gene expression, gene function, pathways, protein-protein interactions, related drugs & compounds and direct links to valuable research reagents and tools such as antibodies, recombinant proteins, clones, expression assays and RNAi reagents. GeneCards was developed over the last 14 years by a world-leading bioinformatics team at the Weizmann Institute of Science in Israel, directed by Marilyn Safran and under the principal investigation of Professor Doron Lancet of the Department of Molecular Genetics, Head of the Crown Human Genome Center, and the incumbent of the Ralph & Lois Silver Professorial Chair of Human Genomics at the Weizmann Institute of Science.

About Xennex

Founded in 2003, Xennex, Inc. (www.xennexinc.com) is a dynamic privately held company that is dedicated to providing Biotechnology, Pharmaceutical and other life sciences companies, as well as organizations dealing with biotechnology intellectual property, the highest level of services and tools to enhance their gene-based research. Xennex’s products help such organizations to optimize their efforts to develop innovative medical products and services.

Xennex’s customers include many of the world’s leading biotech and pharmaceutical companies and organizations dealing with intellectual property, located in North America, Europe and Japan. Xennex’s products are used in hundreds of commercial and academic organizations by tens of thousands of users around the globe.